NCT01105793

Brief Summary

The purpose of this study is to determine the safety of topical FP1198 for the treatment of moderate to severe cyclic breast pain (cyclic mastalgia) and to examine the clinical activity of FP1198.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
20

participants targeted

Target at below P25 for phase_2

Timeline
Completed

Started Jun 2010

Shorter than P25 for phase_2

Geographic Reach
1 country

4 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 13, 2010

Completed
3 days until next milestone

First Posted

Study publicly available on registry

April 16, 2010

Completed
2 months until next milestone

Study Start

First participant enrolled

June 1, 2010

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2011

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2011

Completed
Last Updated

October 26, 2011

Status Verified

October 1, 2011

Enrollment Period

1 year

First QC Date

April 13, 2010

Last Update Submit

October 25, 2011

Conditions

Keywords

cyclic mastalgiacyclic breast painfibrocystic breast disease

Outcome Measures

Primary Outcomes (1)

  • Reduction in breast pain

    six months

Interventions

High dose FP1198 applied once daily to both breasts for 6 treatment cycles.

Eligibility Criteria

Age18 Years+
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • menstruating females at least 18 years of age
  • BMI less than 30
  • moderate to severe breast pain associated with the menstrual cycle
  • in good general health

You may not qualify if:

  • pregnant within the last 6 months
  • has taken in the last 3 months or currently taking hormonal contraception
  • history of malignancy or currently being treated for cancer of the breast or genital organs
  • has had breast implants or breast reduction surgery

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (4)

Women's Health Care

San Diego, California, 92123, United States

Location

Horizons Clinical Research

Denver, Colorado, 80220, United States

Location

Kentucky Medical Research Center

Lexington, Kentucky, 40504, United States

Location

Salt Lake Research

Salt Lake City, Utah, 84107, United States

Location

MeSH Terms

Conditions

Fibrocystic Breast Disease

Interventions

Danazol

Condition Hierarchy (Ancestors)

Breast DiseasesSkin DiseasesSkin and Connective Tissue Diseases

Intervention Hierarchy (Ancestors)

PregnadienesPregnanesSteroidsFused-Ring CompoundsPolycyclic Compounds

Study Design

Study Type
interventional
Phase
phase 2
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 13, 2010

First Posted

April 16, 2010

Study Start

June 1, 2010

Primary Completion

June 1, 2011

Study Completion

June 1, 2011

Last Updated

October 26, 2011

Record last verified: 2011-10

Locations